Bharat Biotech intranasal vaccine has been approved as a booster dose by the Indian government, according to Health Minister Dr Mansukh Mandaviya. The oral Covid vaccine from Bharat Biotech will be available in private clinics and will be introduced on CoWIN from Friday evening.
The Nasal vaccine has been approved by the Indian government. Firstly, it will be available in private hospitals as a heterologous booster. It is now part of the Covid vaccination program. Booster dose for those aged 18 and up, and will most likely be introduced on the Co-WIN platform.
However, it is expected it to be included in the national Covid vaccination programme soon.
The nasal vaccine, BBV154, was approved by the Drugs Controller General of India (DCGI) in November. It is used for limited use in an emergency situation for people over the age of 18 as a recombinant proteins booster dose.
The CoWin portal currently lists Bharat Biotech’s Covaxin, Serum Institute’s Covishield, Covovax, Russian Sputink V and Biological E Ltd’s Corbevax.
On September 6, the vaccine manufacturer announced that its iNCOVACC (BBV154) had been approved by the Drugs Controller General of India for Restricted Use in Emergency Situations for people aged 18 and up.
iNCOVACC was created in collaboration with Washington University in St. Louis. It was designed and developed the recombinant virus – induced vectorial construct and tested its efficacy in vitro experiments.
Bharat Biotech conducted product development related to preclinical safety evaluation, large-scale manufacturing scale up, formulation and delivery device development and human clinical trials.
The Government of India funded a part of the product development and clinical trials through the Department of Biotechnology’s Covid Suraksha programme.
Bharat Biotech intranasal Covid vaccine approved
#BREAKING | Health Ministry approves Bharat Biotech intranasal COVID vaccine. It will be used as a heterologous booster & will be available first in private hospitals, as per sources; 2 drops of vaccine advised – https://t.co/rOqh3LIbyd pic.twitter.com/avCTSswFfH
— Republic (@republic) December 23, 2022